Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.76 |
| ▸ | SRC | P12931 | 6/20 | 0.76 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.76 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.76 |
| ▸ | EGFR | P00533 | 2/20 | 0.76 |
| ▸ | LCK | P06239 | 2/20 | 0.76 |
| ▸ | FYN | P06241 | 2/20 | 0.76 |
| ▸ | CSF1R | P07333 | 2/20 | 0.76 |
| ▸ | YES1 | P07947 | 2/20 | 0.76 |
| ▸ | LYN | P07948 | 2/20 | 0.76 |
| ▸ | RET | P07949 | 2/20 | 0.76 |
| ▸ | HCK | P08631 | 2/20 | 0.76 |
| ▸ | KIT | P10721 | 2/20 | 0.76 |
| ▸ | BCR | P11274 | 2/20 | 0.76 |
| ▸ | BRAF | P15056 | 2/20 | 0.76 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.76 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.76 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.76 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892633 | 0.89 | ABL1 (0.78) | ABL1SRCPKMYT1EPHB6EGFR | |
| SCHEMBL28406220 | 0.89 | ABL1 (0.78) | ABL1SRCPKMYT1EPHB6EGFR | |
| SCHEMBL13626283 | 0.88 | ABL1 (0.78) | ABL1SRCPKMYT1EPHB6EGFR | |
| SCHEMBL1704876 | 0.87 | ABL1 (0.92) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.86 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL28350326 | 0.86 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.86 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL16618598 | 0.85 | ABL1 (1.00) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL1705152 | 0.85 | ABL1 (0.98) | ABL1SRCPKMYT1EPHB6EGFR | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.85 | ABL1 (0.98) | ABL1SRCPKMYT1EPHB6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | Immatics US, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | SHANGHAITECH UNIVERSITY (CN) | 2023-05-02 | — | — | US | disclosed |
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | IL-2RX | 2021-08-19 | — | — | US | disclosed |
| US-10023566-B2 | Dasatinib salts | EGIS GYOGYSZERGYAR ZRT (HU) | 2018-07-17 | — | — | US | disclosed |
| US-9982265-B2 | Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-29 | — | — | US | disclosed |
| US-9968620-B2 | Methods of treating lymphoma using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-20180117043-A1 | USE OF SRC PROTEIN INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF ALZHEIMER'S DISEASE | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180099961-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-04-12 | — | — | US | disclosed |
| US-20120302750-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | disclosed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-8242270-B2 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-8067423-B2 | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-11-29 | — | — | US | disclosed |
| US-20110281867-A1 | COMPOSITIONS AND METHODS OF USE FOR TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-17 | — | — | US | disclosed |
| US-20110212475-A1 | Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7973045-B2 | Anhydrous form of dasatinib and process for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-07-05 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117043-A1 | USE OF SRC PROTEIN INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF ALZHEIMER'S DISEASE | SRC, FYN, CALM1 | ABL1 623/4885SRC 1/4885PKMYT1 852/4885 |
| US-20120302750-A1 | PROCESS FOR PREPARING 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | ABL1 26/4885SRC 54/4885PKMYT1 84/4885 |
| US-20110281867-A1 | COMPOSITIONS AND METHODS OF USE FOR TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION | ABL2, ABL1, LCK | ABL1 2/4885SRC 7/4885PKMYT1 710/4885 |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | BTK, HDAC2, HDAC4 | ABL1 77/4885SRC 29/4885PKMYT1 1922/4885 |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | ABL1 9/4885SRC 176/4885PKMYT1 269/4885 |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | ATG7, SQSTM1, BECN1 | ABL1 1306/4885SRC 515/4885PKMYT1 1337/4885 |
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | TNFRSF9, EGFR, NGFR | ABL1 585/4885SRC 573/4885PKMYT1 1945/4885 |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | CRBN, VHL, CBL | ABL1 9/4885SRC 33/4885PKMYT1 996/4885 |
| US-20180099961-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | ABL1 93/4885SRC 319/4885PKMYT1 445/4885 |
| US-20230355678-A1 | METHODS FOR IMPROVING T CELL EFFICACY | ICOS, IL2, CD4 | ABL1 393/4885SRC 127/4885PKMYT1 712/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | ABL1 263/4885SRC 126/4885PKMYT1 1825/4885 |
| US-10023566-B2 | Dasatinib salts | SRC, PKD1, TP53 | ABL1 8/4885SRC 1/4885PKMYT1 114/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | ABL1 2483/4885SRC 2808/4885PKMYT1 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.